Mueller Sandra M, Schaetz Birgit, Eismann Kathrin, Bergmann Silke, Bauerle Michael, Schmitt-Haendle Matthias, Walter Hauke, Schmidt Barbara, Korn Klaus, Sticht Heinrich, Spriewald Bernd, Harrer Ellen G, Harrer Thomas
Immunodeficiency Center of the Department of Medicine III, University Hospital Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
J Virol. 2007 Mar;81(6):2887-98. doi: 10.1128/JVI.01547-06. Epub 2007 Jan 3.
To determine the influence of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells on the development of drug resistance mutations in the HIV-1 protease, we analyzed protease sequences from viruses from a human leukocyte antigen class I (HLA class I)-typed cohort of 94 HIV-1-positive individuals. In univariate statistical analyses (Fisher's exact test), minor and major drug resistance mutations as well as drug-associated polymorphisms showed associations with HLA class I alleles. All correlations with P values of 0.05 or less were considered to be relevant without corrections for multiple tests. A subset of these observed correlations was experimentally validated by enzyme-linked immunospot assays, allowing the definition of 10 new epitopes recognized by CD8+ T cells from patients with the appropriate HLA class I type. Several drug resistance-associated mutations in the protease acted as escape mutations; however, cells from many patients were still able to generate CD8+ T cells targeting the escape mutants. This result presumably indicates the usage of different T-cell receptors by CD8+ T cells targeting these epitopes in these patients. Our results support a fundamental role for HLA class I-restricted immune responses in shaping the sequence of the HIV-1 protease in vivo. This role may have important clinical implications both for the understanding of drug resistance pathways and for the design of therapeutic vaccines targeting drug-resistant HIV-1.
为了确定1型人类免疫缺陷病毒(HIV-1)特异性CD8+ T细胞对HIV-1蛋白酶耐药性突变发生发展的影响,我们分析了来自94名HIV-1阳性个体的人类白细胞抗原I类(HLA I类)分型队列中病毒的蛋白酶序列。在单变量统计分析(Fisher精确检验)中,主要和次要耐药性突变以及与药物相关的多态性均与HLA I类等位基因存在关联。所有P值小于或等于0.05的相关性在未进行多重检验校正的情况下均被视为具有统计学意义。通过酶联免疫斑点试验对这些观察到的相关性中的一部分进行了实验验证,从而确定了10个由具有相应HLA I类类型患者的CD8+ T细胞识别的新表位。蛋白酶中的几个与耐药性相关的突变起到了逃逸突变的作用;然而,许多患者的细胞仍然能够产生靶向逃逸突变体的CD8+ T细胞。这一结果可能表明在这些患者中,靶向这些表位的CD8+ T细胞使用了不同的T细胞受体。我们的结果支持HLA I类限制性免疫反应在体内塑造HIV-1蛋白酶序列方面的重要作用。这一作用对于理解耐药性途径以及设计针对耐药HIV-1的治疗性疫苗可能具有重要的临床意义。